Disc Medicine Gets $200 Million Loan From Hercules Capital

MT Newswires Live11-08

Disc Medicine (IRON) said Friday it has obtained a $200 million term loan from Hercules Capital (HTGC).

The facility provides funding options to back the expected launch of a confirmatory study of bitopertin in erythropoietic protoporphyria, a phase 2 trial of DISC-0974 in anemia of myelofibrosis and a study in anemia of non-dialysis dependent chronic kidney disease, as well as a phase 2 trial of DISC-3405 in polycythemia vera, the company said.

The loan comprises up to four tranches, three of which can be drawn at the company's option and each maturing in November 2029, the company added.

Shares of Disc Medicine rose nearly 3%, while Hercules Capital shares were marginally higher.

Price: 65.15, Change: +1.82, Percent Change: +2.87

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481488421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481488421","market":"us","top_or_hot":-1,"title":"Disc Medicine Gets $200 Million Loan From Hercules Capital","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> (IRON) said Friday it has obtained a $200 million term loan from Hercules Capital (HTGC).</p><p>The facility provides funding options to back the expected launch of a confirmatory study of bitopertin in erythropoietic protoporphyria, a phase 2 trial of DISC-0974 in anemia of myelofibrosis and a study in anemia of non-dialysis dependent chronic kidney disease, as well as a phase 2 trial of DISC-3405 in polycythemia vera, the company said.</p><p>The loan comprises up to four tranches, three of which can be drawn at the company's option and each maturing in November 2029, the company added.</p><p>Shares of Disc Medicine rose nearly 3%, while Hercules Capital shares were marginally higher.</p><p>Price: 65.15, Change: +1.82, Percent Change: +2.87</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disc Medicine Gets $200 Million Loan From Hercules Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisc Medicine Gets $200 Million Loan From Hercules Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 23:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Disc Medicine (IRON) said Friday it has obtained a $200 million term loan from Hercules Capital (HTGC).The facility provides funding options to back the expected launch of a confirmatory study of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRON","symbol_name":"Disc Medicine","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481488421","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481488421","pubTimestamp":1731080498,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Disc Medicine  said Friday it has obtained a $200 million term loan from Hercules Capital .The facility provides funding options to back the expected launch of a confirmatory study of bitopertin in erythropoietic protoporphyria, a phase 2 trial of DISC-0974 in anemia of myelofibrosis and a study in anemia of non-dialysis dependent chronic kidney disease, as well as a phase 2 trial of DISC-3405 in polycythemia vera, the company said.The loan comprises up to four tranches, three of which can be drawn at the company's option and each maturing in November 2029, the company added.Shares of Disc Medicine rose nearly 3%, while Hercules Capital shares were marginally higher.Price: 65.15, Change: +1.82, Percent Change: +2.87","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRON":"Disc Medicine","BK4135":"资产管理与托管银行","BK4139":"生物科技","HTGC":"海格投资"},"translate_title":"Disc Medicine获得Hercules Capital 2亿美元贷款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTGC":1,"IRON":1},"content_text":"Disc Medicine (IRON) said Friday it has obtained a $200 million term loan from Hercules Capital (HTGC).The facility provides funding options to back the expected launch of a confirmatory study of bitopertin in erythropoietic protoporphyria, a phase 2 trial of DISC-0974 in anemia of myelofibrosis and a study in anemia of non-dialysis dependent chronic kidney disease, as well as a phase 2 trial of DISC-3405 in polycythemia vera, the company said.The loan comprises up to four tranches, three of which can be drawn at the company's option and each maturing in November 2029, the company added.Shares of Disc Medicine rose nearly 3%, while Hercules Capital shares were marginally higher.Price: 65.15, Change: +1.82, Percent Change: +2.87","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481488421"}